Professional Affiliations:

• Fellow, American College of Physicians
• Past President, Renal Physicians Association
• American Society of Transplantation
• Fellow, American Society of Nephrology
• Past-Chair, Board of Trustees, National Kidney Foundation of Michigan

Audio Feature:

    Optimizing Anemia Management in Patients with CKD
    Stream Real Audio | Stream Windows Media

Video Feature:

Hospitals:

• St. John Macomb-Oakland
• St. John North Shores
• William Beaumont - Grosse Pointe
  
• Henry Ford Cottage
• Select Specialty - Grosse Pointe

• Welcome to St. Clair Specialty Physicians!
• Nocturnal Dialysis - A Better Way to a Healthy Life
• Let's Talk: Communicating Effectively with Your Physician
• The Importance of Dental Care for Transplant Recipients
• Why are BUN and creatinine important to monitor in kidney patients?
• What is all the fuss about the treatment of anemia?

• Managed Care Guidelines for Management of Chronic Kidney Disease
  
  [Full text available in Adobe PDF format]
  Provenzano, R, et al. Managed Care Guidelines for Management of Chronic Kidney Disease, Suppl. Managed Care, Vol. 12, No. 3, March 2003.
• Comparison of Vancomycin Versus Cefazolin as Initial Therapy for Peritonitis in Peritoneal Dialysis Patients
  
  [Download full text article in Adobe PDF format]
  Khairullah, Q., Provenzano, R., Ahmed, A., Tayeb, T., Balakrisnan, B., Comparison of Vancomycin Versus Cefazolin as Initial Therapy for Peritonitis in Peritoneal Dialysis Patients, In press, Perit Dial Int 2002; 22:339-344.
  
• Current Essentials of Diagnosis & Treatment in Nephrology and Hypertension
  
  [McGraw Hill Publisher Link]
  Provenzano, R., Anemia Management in Chronic Kidney Disease. "Current Essentials of Diagnosis & Treatment in Nephrology and Hypertension," Nissenson, A., Berns, J., Lerma, E. Editors, McGraw Hill Publishers, April 2007.
  BOOK OVERVIEW: CurrentDiagnosis & Treatment in Nephrology and Hypertension offers a practical, clinical review of the state-of-the-art approach to the management of kidney diseases and hypertension--in the popular CURRENTS format. You'll find coverage of all the major diseases and disorders plus all the leading therapies.
• Role of Aldosterone in Left Ventricular Hypertrophy among African-American Patients with End-Stage Renal Disease on Hemodialysis
  
  [View listing on Karger.com]
  Steigerwalt, S., Zafar, A., Mesiha, N., Gardin, J., Provenzano, R., Role of Aldosterone in Left Ventricular Hypertrophy among African-American Patients with End-Stage Renal Disease on Hemodialysis, American Journal of Nephrology 2007; 27:159-163.
  ABSTRACT: Recently, serum aldosterone levels have been reported to play a significant role in cardiac hypertrophy. One study of Japanese patients correlated aldosterone levels with the degree of left ventricular hypertrophy (LVH) in those undergoing hemodialysis. However, the role of aldosterone in LVH in non-Japanese patients with end-stage renal disease (ESRD) has not been established. 
• Prevalence and Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Diabetes and Chronic Kidney Disease
  
  [Full text available on Oxford Journals]
  Lorber, D., Provenzano, R., McClellan, W., Prevalence and Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Diabetes and Chronic Kidney Disease, Endocrine Practice, Vol. 12, No. 5, pp. 506-513, September/October 2006.
  ABSTRACT: The effectiveness of extended dosing of epoetin alfa beyond once-weekly (QW) has not been well explored in patients being treated for anaemia of chronic kidney disease (CKD). The current study was undertaken to assess the effectiveness of extended dosing in maintaining haemoglobin (Hb) levels in this population.
• Extended Epoetin Alfa Dosing as Maintenance Treatment for the Anemia of Chronic Kidney Disease
  
  [View article listing on Pubmed.gov]
  Provenzano, R., Bhaduri, S., Singh, A., Extended Epoetin Alfa Dosing as Maintenance Treatment for the Anemia of Chronic Kidney Disease: The PROMPT Study, Clinical Nephrology, Vol. 64, No. 2, pp. 113-123, August 2005.
  AIM: To determine whether extended epoetin alfa dosing schedules of up to once every four weeks are as effective as weekly dosing in maintaining hemoglobin (Hb) levels in patients with anemia of chronic kidney disease (CKD).
  
• A Single Center Experience in the Use of Polyurethaneurea Arteriovenous Grafts
  
  [View article listing on Pubmed.gov]
  Jefic, D., Reddy, P., Flynn, L., Provenzano, R.,  A Single Center Experience in the Use of Polyurethaneurea Arteriovenous Grafts, Nephrology News and Issues, Vol. 19, No. 8 , pp. 44-47, July 2005.
  BACKGROUND: Polytetrafluoroethylene (PTFE) grafts often require temporary catheters, which increase costs as well as risk of infection, bleeding, and poor blood flow. Polyurethaneurea (PUU) grafts can be cannulated within 24 hours of placement, avoiding the need for temporary catheters.
• Core Curriculum in Nephrology: Economics of Clinical Nephrology Practice
  
  [Full text available in Adobe PDF format]
  Provenzano, R., Nissenson, A., Core Curriculum in Nephrology: Economics of Clinical Nephrology Practice, American Journal of Kidney Diseases, Vol. 44, No. 1, pp. 168-178, July 2004.
  ABOUT: Economics of Clinical Nephrology Practice” emphasizes learning the information needed to make the best choices for clinical practice, and as a result having a productive and rewarding career as a clinical nephrologist.
• Once-Weekly Epoetin Alfa for Treating the Anemia of Chronic Kidney Disease
  
  [View article listing on isiknowledge.com]
  Provenzano, R., Garcia-Mayol, L., Suchinda, P., Von Hartitzsch, B., Woollen, S.B., Zabaneh, R., Fink, J.C. and the POWER Study Group, Once-Weekly Epoetin Alfa for Treating the Anemia of Chronic Kidney Disease, Clinical Nephrology, Vol. 61, No 6, pp. 392-405, June 2004.
  BACKGROUND AND AIM: Anemia occurs in approximately 47% of patients with chronic kidney disease (CKD) not on dialysis. Recombinant human erythropoietin (r-HuEPO, epoetin alfa) has been proven safe and effective for anemia treatment in patients with CKD using a three times-weekly regimen. The current study was conducted to evaluate the clinical safety and efficacy of a less frequent dosing regimen (once weekly) in this population.
• Early Detection of Prostate Cancer in the ESRD Population
  
  [View article listing on pubMed.gov]
  Khairullah, Q.T., Pamatmat, S.D., Chatha, M., Provenzano, R., Telang, D., Temple, M., Early Detection of Prostate Cancer in the ESRD Population, Clinical Nephrology, Vol. 61, No. 5, May 2004.
  BACKGROUND: There are currently no prostate cancer screening guidelines specific to the end-stage renal disease (ESRD) population. With this in mind, we evaluated the clinical usefulness of digital rectal examination (DRE), serum total prostate-specific antigen (PSA), prostate-specific antigen density (PSAD) and transrectal ultrasound (TRUS) in predicting prostate cancer in men with ESRD.
• The Value of Integrating a Vascular Surgeon into a Nephrology Practice
  
  [View article listing on pubmed.gov]
  Provenzano, R., Flynn, L., The Value of Integrating a Vascular Surgeon into a Nephrology Practice, Nephrology News & Issues, Vol. 17, No. 8, pp. 49-53, July 2003.
• The Nephrology Nurse's Role in Improved Care of Patients with Chronic Kidney Disease
  
  [Full article text available on Findarticles.com]
  Provenzano, R., Compton, A., Johnson, CA., The Nephrology Nurse’s Role in Improved Care of Patients with Chronic Kidney Disease, Nephrology Nursing Journal, Vol. 29, No. 4, pp. 331-336, (August) 2002.
  ABSTRACT: Several authors have advocated the use of multidisciplinary patient care teams to provide the most effective and efficient care for patients with CKD (Grady, Casde, & Sibley, 1996; Self et al., 1999). This article will review selected aspects of CKD management, describe the contributions of nephrology nurses practicing within a multidisciplinary CKD clinic, and discuss national CKD initiatives and educational materials that will assist nephrology nurses in caring for CKD patients.
  
• Frequency of HB Testing and Anemia Diagnosis in Patients with Chronic Kidney Disease During Pre and Postdialysis Period.
  
  [Full text available in Adobe PDF format via ScienceDirect]
  Wish, J., Provenzano, R., Shulman, K., Law, A, Nassar, G., Frequency of HB Testing and Anemia Diagnosis in Patients with Chronic Kidney Disease During Pre and Postdialysis Period.  National Kidney Foundation Clinical Meetings, Orlando, FL, 2007.
• C.E.R.A. Administered at Extended Dosing Intervals Corrects Anemia and Maintains Stable Hemoglobin Levels in Patients with Chronic Kidney Disease (CKD) not on Dialysis
  
  Provenzano, R., Schmidt, R., Dalton, C., Beswick, R., Nassar, G., C.E.R.A. Administered at Extended Dosing Intervals Corrects Anemia and Maintains Stable Hemoglobin Levels in Patients with Chronic Kidney Disease (CKD) not on Dialysis. ESRD Forum Meeting, Baltimore, MD, 2007.
• Use of Aldosterone Antagonists (AA) Are Associated with Achieved Blood Pressure (BP) Control in Chronic Kidney Disease (CKD)
  
  Topf, J., Steigerwalt, S., Provenzano, R., Use of Aldosterone Antagonists (AA) Are Associated with Achieved Blood Pressure (BP) Control in Chronic Kidney Disease (CKD). American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• CKD (Chronic Kidney Disease) Clinics Improve Anemia, Lipids and Arrest the Decline of GFR
  
  Topf, J., Provenzano, R., Abud, G., CKD (Chronic Kidney Disease) Clinics Improve Anemia, Lipids and Arrest the Decline of GFR, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• A Double-Blind, Placebo-Controlled, Randomized Phase III Study of the Safety of Ferumoxytol – A New Intravenous Iron Replacement Therapy
  
  Singh, A., Besarab, A. Bolton, W., Pereira, B, Provenzano, R., Rao, M., Spinowitz, B., A Double-Blind, Placebo-Controlled, Randomized Phase III Study of the Safety of Ferumoxytol – A New Intravenous Iron Replacement Therapy, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• Parenteral Iron Therapy with Ferumoxytol in Hemodialysis: A Phase III Study
  
  Besarab, A., Bolton, W., Pereira, B., Provenzano, R., Singh, A., Rao, and Spinowitz, B. Parenteral Iron Therapy with Ferumoxytol in Hemodialysis: A Phase III Study, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• Ferumoxytol as Intravenous Iron Replacement Therapy in Chronic Kidney Disease (CKD) Patients Not on Dialysis – Evaluation of Safety and Efficacy in Two Phase III Studies
  
  Spinowitz, B., Besarab, A., Bolton, W., Pereira, B., Provenzano, R., Rao, M., Singh, A. Ferumoxytol as Intravenous Iron Replacement Therapy in Chronic Kidney Disease (CKD) Patients Not on Dialysis – Evaluation of Safety and Efficacy in Two Phase III Studies, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• Blood Pressure (BP) Control by Race, Gender and Chronic Kidney Disease (CKD) Stage in a CKD Clinic
  
  Topf, J., Steigerwalt, S., Provenzano, R., Blood Pressure (BP) Control by Race, Gender and Chronic Kidney Disease (CKD) Stage in a CKD Clinic, American Society of Hypertension 21st Annual Scientific Meeting, New York, NY, 2006.
• Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) Administered Once Every 2 Weeks Effectively Corrects Anemia in Patients with Chronic Kidney Disease (CKD) on Dialysis and Not on Dialysis
  
  Provenzano, R., Dougherty, F., Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) Administered Once Every 2 Weeks Effectively Corrects Anemia in Patients with Chronic Kidney Disease (CKD) on Dialysis and Not on Dialysis. National Kidney Foundation Clinical Meetings, Chicago, IL, 2006.
• The Impact of Avoiding Both Steroids and Calcineurin Inhibitors on Polyomavirus-Associated Nephropathy in Kidney Transplantation
  
  Brar, N., Butcher, D., El-Ghoroury, M., Provenzano, R., The Impact of Avoiding Both Steroids and Calcineurin Inhibitors on Polyomavirus-Associated Nephropathy in Kidney Transplantation, National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• C-Reactive Protein Levels Do Not Predict Acute Rejection in Kidney Transplant Recipients
  
  Butcher, D., El-Ghoroury, M., Bellovich, K., Provenzano, R., C-Reactive Protein Levels Do Not Predict Acute Rejection in Kidney Transplant Recipients, National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• Pretransplant C-Reactive Protein Levels Do Not Predict Renal Function or Graft Survival at One Year
  
  Butcher, D., Kassar, A., Bellovich, K., El-Ghoroury, M., Provenzano, R., Pretransplant C-Reactive Protein Levels Do Not Predict Renal Function or Graft Survival at One Year.  American Society of Nephrology, Philadelphia, PA, 2005.
• Impact of Avoiding Loading Dose of Sirolimus on Wound Complication After Kidney Transplant. A Single Center Experience
  
  Ayran, M., Jabri, M., El-Ghoroury, M., Oh, H., Provenzano, R., Impact of Avoiding Loading Dose of Sirolimus on Wound Complication After Kidney Transplant. A Single Center Experience.  American Transplant Congress, Seattle, WA , 2005.
• Baxiliximab Versus Thymoglobulin Induction for Steroid-Free Maintenance Immunosuppression in Live Kidney Transplant Recipients
  
  Butcher, D., El-Ghoroury, M., Provenzano, R., Granger, D., Oh, H., Baxiliximab Versus Thymoglobulin Induction for Steroid-Free Maintenance Immunosuppression in Live Kidney Transplant Recipients, Transplant Immunosuppression 2005: Improving Recipient Outcome, University of Minnesota, 2005. (Oral Presentation)
• Prevalence and Treatment of Anemia in Patients with Hypertension and Chronic Kidney Disease
  
  McClellan, W., Provenzano, R., Prevalence and Treatment of Anemia in Patients with Hypertension and Chronic Kidney Disease.  Heart Failure Society of America, 9th Annual Scientific Meeting, Boca Raton, FL, 2005.
• Anemia Outcomes from a Medical-Assistant Driven Anemia Protocol to Treat Patients and Move Toward Monthly Epoetin Dosing.
  
  Topf, J., Abud, G., Maria, V., Provenzano, R., Anemia Outcomes from a Medical-Assistant Driven Anemia Protocol to Treat Patients and Move Toward Monthly Epoetin Dosing. American Society of Nephrology, Philadelphia, PA, 2005.
• The Role of Home Blood Pressure Monitoring (HBPM) in the Control of Hypertension in Renal Transplant Recipients
  
  Awosika, B., Makos, G., Steigerwalt, S., El-Ghoroury, M., Provenzano, R., The Role of Home Blood Pressure Monitoring (HBPM) in the Control of Hypertension in Renal Transplant Recipients. American Society of Transplantation, Boston, MA, 2004.
• Long Term AV Graft Survival of Polyurethane (Vectra®) Grafts.
  
  Rankin, S., Provenzano, R., Flynn, L., Long Term AV Graft Survival of Polyurethane (Vectra®) Grafts. American Society of Nephrology, San Diego, CA, 2003.
• Safety and Efficacy of Sirolimus, Low Dose Tacrolimus and Early Steroid Withdrawal in Patients with Cadaveric Renal Allographs: A Comparative Study
  
  Nagrecha, N., El-Ghoroury, M., Provenzano, R., Safety and Efficacy of Sirolimus, Low Dose Tacrolimus and Early Steroid Withdrawal in Patients with Cadaveric Renal Allographs: A Comparative Study. American Society of Nephrology Meeting, St. Louis, MO, 2004.
• Incidence and Risk Factors of Nocardiosis in Renal Transplant Recipients
  
  Pasumarthy, A., Rankin, S., El-Ghoroury, M., Johnson, L.B., Provenzano, R.,  Incidence and Risk Factors of Nocardiosis in Renal Transplant Recipients.  American Society of Nephrology, San Diego, CA, 2003.
• Extended Dosing of PROCRIT (Epoetin Alfa) Effectively Treats Anemia and Improves Quality of Life in Patients with Diabetes and CKD
  
  Provenzano, R., Extended Dosing of Procrit (Epoetin Alfa) Effectively Treats Anemia and Improves Quality of Life in Patients with Diabetes and CKD.  National Kidney Foundation Clinical Meetings, Chicago, IL, 2004.
• Prospective, Randomized Evaluation of Extended Epoetin Alfa Dosing for Treatment of Anemia of Chronic Kidney Disease (CKD): PROMPT Interim Analysis
  
  Provenzano, R., Bhaduri, S., Tang, K.L., Klausner, M., Singh, A.,  Prospective, Randomized Evaluation of Extended Epoetin Alfa Dosing for Treatment of Anemia of Chronic Kidney Disease (CKD): PROMPT Interim Analysis.  American Society of Nephrology, San Diego, CA, 2003.
• Spironolactone Use Does Not Increase Serum Potassium in End Stage Renal Disease Patients on Hemodialysis.
  
  Reddy, P., Steigerwalt, S., Brar, B., Provenzano, R., Spironolactone Use Does Not Increase Serum Potassium in End Stage Renal Disease Patients on Hemodialysis.  American Society of Nephrology, San Diego, CA, 2003.
• Safety and Efficacy of Calcineurin and Steroid Avoidance in Living Donor Renal Allografts
  
  Reddy, P., Brar, B., El-Ghoroury, M., Provenzano, R., Oh, H., Fasola, C., Safety and Efficacy of Calcineurin and Steroid Avoidance in Living Donor Renal Allografts.  American Society of Nephrology, San Diego, CA, 2003.
• Adequacy of Inpatient Versus Outpatient Hemodialysis in End Stage Renal Disease Patients: A Comparative Study.
  
  Brar, B., Tayeb., J., Reddy, P., Goushaw, P., Provenzano, R.,  Adequacy of Inpatient Versus Outpatient Hemodialysis in End Stage Renal Disease Patients: A Comparative Study.  American Society of Nephrology, San Diego, CA, 2003.
• Aldosterone Is Involved in Left Ventricular Hypertrophy in African American Males with End Stage Renal Disease Treated with Hemodialysis
  
  Steigerwalt, S., Mesiha, N., Zafar, A., Gardin, J., Provenzano, R.,  Aldosterone Is Involved in Left Ventricular Hypertrophy in African American Males with End Stage Renal Disease Treated with Hemodialysis.  American Society of Nephrology, San Diego, CA, 2003.
• Once-Weekly (QW) Treatment with Epoetin Alfa in Patients with Anemia Due to Chronic Kidney Disease (CKD)
  
  [Article listing on pubMed.gov]
  Provenzano, R., Morrison, L., Once-Weekly (QW) Treatment with Epoetin Alfa in Patients with Anemia Due to Chronic Kidney Disease (CKD): Preliminary Analysis. J Am Soc Nephrol 2001:12:A1227.
  OBJECTIVE: To describe the characteristics and prevalence of anemia in patients with diabetes and chronic kidney disease (CKD) not receiving dialysis and to evaluate the efficacy and safety of once-weekly (QW) epoetin alfa for the treatment of anemia in these patients.
• An Analysis of Bone Disease-Related Medication Use Throughout ESRD.
  
  Johnson, C., McCarthy, J., Tello, A., Provenzano, R., Deane, J. An Analysis of Bone Disease-Related Medication Use Throughout ESRD. National Conference on Dialysis, New Orleans, LA, 2001